Literature DB >> 27373289

[A Meta-analysis of the accuracy of interferon-γ release assays in differentiating intestinal tuberculosis from Crohn's disease in Asia].

H Xu1, Y Li, J M Qian.   

Abstract

OBJECTIVE: This meta-analysis assessed the value of interferon-γ release assays (IGRAs) in the differential diagnosis of intestinal tuberculosis (ITB) from Crohn's disease (CD).
METHODS: Systematic search without language restriction was conducted in the main computerized databases until June 2015. Studies that have evaluated the performance of IGRAs (QuantiFERON-TB Gold or T-SPOT.TB) in distinguishing ITB from CD were eligible. Main outcome measures included sensitivity and specificity. Area under the curve (AUC) of the summary receiver operating characteristic (sROC) curve was used to evaluate the accuracy of IGRAs.
RESULTS: Twelve studies (all from Asia) were finally included. The pooled sensitivity and specificity of IGRAs for the differential diagnosis of ITB from CD were 82.8% (95%CI 78.4%-86.6%) and 86.7% (95%CI 83.2%-89.6%) respectively. The positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 6.870 (95%CI 5.345-8.830) and 0.171 (95%CI 0.105-0.279). The diagnostic odds ratio was 44.030 (95%CI 27.964-69.325). And the AUC of sROC was 0.939.
CONCLUSIONS: IGRAs have a high sensitivity and specificity for the diagnosis of ITB, and specificity is consistent from study to study. IGRAs may be considered as a supplementary method in the differential diagnosis of ITB from CD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27373289     DOI: 10.3760/cma.j.issn.0578-1426.2016.07.010

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  5 in total

1.  The risk factor of false-negative and false-positive for T-SPOT.TB in active tuberculosis.

Authors:  Li Di; Yan Li
Journal:  J Clin Lab Anal       Date:  2017-06-08       Impact factor: 2.352

2.  Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn's disease in patients with positive results.

Authors:  Yujie Zhao; Meilin Xu; Liang Chen; Zhanju Liu; Xiaomin Sun
Journal:  Therap Adv Gastroenterol       Date:  2020-05-18       Impact factor: 4.409

3.  Diagnostic Utility of Non-invasive Tests for Inflammatory Bowel Disease: An Umbrella Review.

Authors:  Jin-Tong Shi; Yuexin Zhang; Yuehan She; Hemant Goyal; Zhi-Qi Wu; Hua-Guo Xu
Journal:  Front Med (Lausanne)       Date:  2022-07-11

4.  Development and validation of a new algorithm model for differential diagnosis between Crohn's disease and intestinal tuberculosis: a combination of laboratory, imaging and endoscopic characteristics.

Authors:  Yi Lu; Yonghe Chen; Xiang Peng; Jiayin Yao; Weijie Zhong; Chujun Li; Min Zhi
Journal:  BMC Gastroenterol       Date:  2021-07-13       Impact factor: 3.067

5.  Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial.

Authors:  Satimai Aniwan
Journal:  Clin Endosc       Date:  2022-03-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.